Aldeyra Therapeutics (trading under the Nasdaq ticker ALDX) was founded as a biotechnology venture focused on translating advanced chemical and immunological research into therapeutic treatments. Over the years, the company advanced multiple drug candidates through preclinical and human clinical trial phases, raised capital through public equity offerings, and navigated complex regulatory evaluation pathways with the U.S. Food and Drug Administration (FDA) regarding its flagship inflammatory and immune-modulating drug pipelines.